Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | LTA4H | P09960 | 1/20 | 0.76 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | MPO | P05164 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8810102 | 0.90 | LTA4H (0.94) | KDM4EALDH1A1LTA4HEPHX2GAA | |
| SCHEMBL12500537 | 0.90 | KDM4E (0.69) | KDM4EALDH1A1LTA4HEPHX2GAA | |
| SCHEMBL3272134 | 0.90 | GAA (0.91) | KDM4EALDH1A1LTA4HEPHX2GAA | |
| SCHEMBL11881258 | 0.90 | GAA (0.91) | KDM4EALDH1A1LTA4HEPHX2GAA | |
| SCHEMBL3265257 | 0.89 | SIGMAR1 (0.70) | KDM4EALDH1A1LTA4HEPHX2GAA | |
| SCHEMBL27228 | 0.88 | GAA (0.95) | KDM4EALDH1A1GAAMAPTMPO | |
| Hydrochloric Acid SCHEMBL7320578 | 0.87 | SIGMAR1 (0.68) | KDM4EALDH1A1LTA4HEPHX2GAA | |
| SCHEMBL25432637 | 0.86 | GAA (0.91) | KDM4EALDH1A1GAAMAPTMPO | |
| Hydrochloric Acid SCHEMBL1983401 | 0.86 | GAA (1.00) | KDM4EALDH1A1GAAMAPTCYP2D6 | |
| Ammonia Solution, Strong SCHEMBL23581968 | 0.86 | GAA (0.91) | KDM4EALDH1A1GAAMAPTMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | ACELOT,INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | ACELOT, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | ACELOT, INC. | 2019-07-11 | — | — | US | disclosed |
| US-9920010-B2 | CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-03-20 | — | — | US | disclosed |
| EP-3004082-B1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-20160107997-A1 | CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-04-21 | — | — | US | disclosed |
| EP-3004082-A1 | CXCR7 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014191929-A1 | CXCR7 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-12-04 | — | — | WO | disclosed |
| US-4977144-A | ADENOSINE AGONISTS | CIBA-GEIGY CORPORATION (US) | 1990-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107997-A1 | CXCR7 RECEPTOR MODULATORS | CXCR1, CXCR5, CXCR2 | KDM4E 4180/4885ALDH1A1 997/4885LTA4H 1192/4885 |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | APP, PSEN2, PSEN1 | KDM4E 4863/4885ALDH1A1 4713/4885LTA4H 1435/4885 |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | APP, PSEN2, PSEN1 | KDM4E 4816/4885ALDH1A1 4482/4885LTA4H 1969/4885 |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | HTT, TARDBP, SNCA | KDM4E 4369/4885ALDH1A1 4676/4885LTA4H 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.